Procept BioRobotics said its Aquablation procedure uses waterjet resection to precisely eradicate tissue without requiring full prostate removal.

AquaBeam is an image-guided robotic system for use in minimally-invasive urologic surgery.

In August 2020, autonomous vehicles, industrial automation for manufacturing and supply chains, and healthcare robotics continued to receive funding.

Procept BioRobotics has raised $118 million in an equity round. The Redwood Shores, Calif.-based company plans to use the funding on the commercialization of its Aquablation robotic prostate surgery for benign prostate hyperplasia. Procept said new backer Viking Global Investors led the round, joined by Perceptive Advisors and existing investors including CPMG. The Aquablation treatment…

Procept BioRobotics said today that it won de novo clearance from the FDA for its Aquabeam device for treating benign prostate hyperplasia, saying it plans to have the device on the U.S. market early next year. Redwood Shores, Calif.-based Procept said the federal safety watchdog used the 181-patient Water study to inform its decision. The trial, comparing Aquablation…

Procept BioRobotics said today that it launched a clinical trial aimed at winning reimbursement approval in France for its AquaBeam prostate treatment. Redwood Shores, Calif.-based Procept said the 30-patient Francais Water study is designed to evaluate the safety and effectiveness of prostate ablation via waterjet in treating benign prostate hyperplasia in men aged 45 to 80.…

PROCEPT BioRobotics announced today that the first patients were treated in its WATER II Study, a clinical trial testing the safety and efficacy of Aquablation delivery by its surgical robotic AquaBeam System to treat benign prostatic hyperplasia. The trials test the use of the system in prostates 80 to150 mL and will enroll 100 patients…